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AbsTrACT
advances in technology have led to a massive 
expansion in the capacity for genomic analysis, with a 
commensurate fall in costs. the clinical indications for 
genomic testing have evolved markedly; the volume 
of clinical sequencing has increased dramatically; 
and the range of clinical professionals involved in the 
process has broadened. there is general acceptance 
that our early dichotomous paradigms of variants being 
pathogenic–high risk and benign–no risk are overly 
simplistic. there is increasing recognition that the clinical 
interpretation of genomic data requires significant 
expertise in disease–gene- variant associations specific to 
each disease area. inaccurate interpretation can lead to 
clinical mismanagement, inconsistent information within 
families and misdirection of resources. it is for this reason 
that ’national subspecialist multidisciplinary meetings’ 
(mDms) for genomic interpretation have been articulated 
as key for the new nHs Genomic medicine service, of 
which Cancer Variant interpretation Group UK (CanViG- 
UK) is an early exemplar. CanViG- UK was established 
in 2017 and now has >100 UK members, including at 
least one clinical diagnostic scientist and one clinical 
cancer geneticist from each of the 25 regional molecular 
genetics laboratories of the UK and ireland. through 
CanViG- UK, we have established national consensus 
around variant interpretation for cancer susceptibility 
genes via monthly national teleconferenced mDms and 
collaborative data sharing using a secure online portal. 
We describe here the activities of CanViG- UK, including 
exemplar outputs and feedback from the membership.
bACkground
Clinical utility of cancer susceptibility genes 
(Csgs)
Analysis of germline (constitutional) variants in 
CSGs constitutes approximately one- quarter of 
activity in NHS Molecular Diagnostic Laboratories 
in England.1 Following identification of a patho-
genic variant (PV) in a CSG, incidence of/mortality 
from future cancers may be mitigated via (1) risk- 
reducing surgery (eg, mastectomy, gastrectomy, 
salpingo- ophorectomy and colectomy); (2) chemo-
prevention; (3) intensive screening; and (4) lifestyle 
modification.2 Family members negative for the 
familial CSG- PV can be spared anxiety and unnec-
essary screening. Many CSGs are associated with 
a pattern of cancer risk that is late- onset, variably 
penetrant and of autosomal dominant inheritance. 
PV- positive family members identified via cascade 
screening are often distributed across disparate 
genomics services.
Erroneous interpretation of CSG variant patho-
genicity can therefore result in (1) discordant 
management within families, (2) serious clinical 
consequences for individuals and (3) misdirection 
at population level of resources for screening and 
prevention.3–5 Increasingly, CSG- PVs are used as 
predictive biomarkers to inform cancer therapy. 
For all these reasons, robust, rapid, accurate variant 
analysis and interpretation of disease risk are crit-
ical to effective delivery of germline cancer genetics 
and improving outcomes for patients.
Evolving landscape of variant interpretation in 
germline cancer genetics
In the late 1990s, within a few years of identification 
of the relevant genes, laboratory analysis of CSGs 
became available in the UK via family cancer clinics.2 
If the cancer phenotype ascribed to the gene matched 
that found in the proband/family under study, with 
little additional evidence, a rare variant would often 
be labelled as pathogenic and thus causative.6 Subse-
quent large- scale population sequencing studies have 
revealed the degree of innocuous variation present in 
the human genome (and indeed in disease- associated 
genes) and ‘downgrading’ of many erroneously 
labelled PVs has been required.7 An era of caution 
followed, with much greater recourse to labelling of 
variants as ‘variants of uncertain significance’ (VUS/
VOUS). However, lack of systems for sharing new 
evidence has meant that many families have spent 
years in limbo with their ‘VUS’, even when data had 
long been available by which classification of their 
variant could be downgraded or upgraded.
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box 1 CanVIg objectives
The purpose of Cancer Variant Interpretation Group UK 
(CanVIG- UK) is to advance outcomes for patients by improving 
the accuracy and consistency of interpretation of variants in 
Cancer Susceptibility genes across the UK clinical- laboratory 
community. We have six specific objectives:
1. Creation of a national multidisciplinary professional network 
and regular forum.
2. Training and education.
3. Detailed specification for germline cancer genetics of the UK- 
ACGS Best Practice Guidelines for Variant Interpretation.
4. Ratification of additional guidance in germline cancer 
genetics relevant to the UK clinical- laboratory community.
5. Development of an online platform to facilitate information 
sharing and variant interpretation within the UK clinical- 
laboratory community.
6. UK contribution to international variant interpretation 
endeavours. 
Sharing of clinical variant data was somewhat improved with 
the advent of locus- specific databases (LSDs), such as Breast 
Cancer Information Core and Leiden Open Variant Data-
bases.8–11 However, the curation of clinical and molecular data 
in LSDs often remains suboptimal, with (1) erroneous nomencla-
ture, (2) duplication of entries and (3) use of differing classifica-
tion systems resulting in contradictory assignations.12
Using Myriad Genetics data from ~70 000 genetic tests 
for hereditary breast and ovarian cancer, in 2007, Easton and 
colleagues published a landmark multifactorial analysis through 
which ‘odds of causality’ were mathematically generated for 
1433 variants using clinical, pedigree and allelic data.13 In 2008, 
International Agency for Research on Cancer (IARC) collabo-
rators published the first formal five point variant interpreta-
tion system for CSGs, which included numeric thresholds for 
the probability of pathogenicity.14 Expert cancer susceptibility 
consortia such as the Evidence- based Network for the Inter-
pretation of Germline Mutant Alleles (ENIGMA) and the 
International Society for Gastrointestinal Hereditary Tumours 
(InSIGHT) further evolved these multifactorial variant classifi-
cation systems to incorporate tumour phenotype and in silico 
predictions.15–17 However, ENIGMA/InSIGHT approaches 
require statistical genetic–epidemiological analyses of large 
curated data series and are not reproducible by an individual 
diagnostic laboratory seeking to classify in a clinically relevant 
timescale a newly identified variant.
In 2015, the American College of Medical Geneticists 
(ACMG) published a variant interpretation framework enabling 
the combination by a diagnostic laboratory of disparate evidence 
sources for a newly identified genomic variant.18 The ACMG 
framework has subsequently been further evolved under the 
auspices of ClinGen, including (1) specification for how it is 
applied to particular genes and/or diseases (including TP53, 
CDH1 and PTEN); (2) deeper specification of particular criteria 
(eg, functional assays); and (3) exposition of the underpinning 
Bayesian model.19–23
Coordinated national uk approaches in variant interpretation
In 2016, with endorsement from NHS England and Health 
Education England, it was agreed formally by the UK Asso-
ciation of Clinical Genomic Science (UK- ACGS) to adopt the 
ACMG variant interpretation framework.24 25 The UK- ACGS 
established national groups for rare disease, germline cancer 
genetics, cardiac disease and hypercholesterolaemia to develop 
and disseminate practice in the application of the ACMG variant 
interpretation framework.24 In parallel was recognition within 
the NHS Genomic Medicine Service of the need for national 
subspecialist genomics MDMs.26 27 In response to these dual 
recommendations, Cancer Variant Interpretation Group UK 
(CanVIG- UK) was initiated in 2017.
CAnCEr VArIAnT InTErprETATIon group uk
The purpose of CanVIG- UK is to advance outcomes for patients 
by improving the accuracy and consistency of interpretation of 
variants in CSGs across the UK clinical genetics and molecular 
diagnostic laboratory communities (hereafter termed the UK 
clinical- laboratory community). We aim to progress this goal by 
advancing six objectives (see box 1).
Creation of a national multidisciplinary professional network 
and regular forum
CanVIG- UK has grown to now include >100 members, incor-
porating clinical and laboratory representation from each of the 
25 Molecular Diagnostic Laboratories and Clinical Genetics 
Services of the UK (NHS) and Ireland (see collaborators). This 
group comprises roughly equal proportions of clinical scientists 
and clinical geneticists, with two- thirds working exclusively or 
predominantly in cancer genetics (figure 1):
 ► The monthly teleconferenced MDM provides a forum to 
which problematic variants/cases are submitted. The vari-
ants submitted to the monthly variant surgery are circulated 
1 week in advance. CanVIG- UK members are asked (1) to 
ascertain whether additional cases and/or laboratory data 
exist locally and (2) to undertake local, independent clas-
sification of the variant. The relevant clinical and labora-
tory data are presented by the nominating laboratory. This 
is followed by input of any additional information by the 
broader CanVIG- UK group and a discussion regarding the 
legitimacy of the ACMG criteria awarded. Following this 
discussion and an online postdiscussion poll, a consensus 
CanVIG classification is generated (see online supplementary 
table 1). A detailed date- stamped CanVIG variant summary 
sheet is generated (see online supplementary appendix 2), 
which is circulated by email, uploaded to the CanVar- UK 
portal and submitted to ClinVar.
 ► The CanVIG- UK network is active throughout the month 
via the email forum, through which urgent queries can be 
debated and addressed.
Training and education
The discussion of cases at the MDM also provides valuable 
education for the clinical- laboratory community regarding appli-
cation of the ACMG framework and the vagaries of the evidence 
sources used (see figure 2). Additionally, through CanVIG- UK, 
we have supported training of the broader UK genetics and 
oncology communities in variant interpretation for CSGs.
detailed specification for germline cancer genetics of the uk-
ACgs best practice guidelines for Variant Interpretation
On behalf of the UK- ACGS, the rare disease variant interpreta-
tion group has generated and updates annually a highly detailed 
specification of the ACMG variant interpretation framework .24 
In cancer susceptibility, we typically observe variants relating 
to late- onset, common phenotypes. De novo and biallelic 
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Figure 1 overview of the CanViG- UK membership profile (survey of 
CanViG- UK members, performed on 29 october 2019, return rate 83/103 
(81%). HBoC, hereditary breast and ovarian cancer; mmR, mismatch repair. 
CanViG- UK, Cancer Variant interpretation Group UK.
paradigms are infrequent. We are typically much more reliant 
on variant frequency from case series and functional assays. 
Thus, an important remit for CanVIG- UK has been to develop 
a detailed specification of the UK- ACGS framework for these 
types of evidence to be used for CSG variant interpretation (see 
online supplementary appendix 1).
ratification of additional guidance in germline cancer 
genetics relevant to the uk clinical-laboratory community
Historically, the first presentation to the family cancer clinic was 
typically an unaffected individual, concerned by a significant 
family history. Increasingly, genetic analysis is now performed 
as part of routine work- up at cancer diagnosis, either through 
analysis of a germline sample or through therapeutically moti-
vated molecular analysis of the tumour. In both contexts, (1) 
focused testing of one or two genes has often been superseded 
by broad ‘cancer panels’ containing dozens or hundreds of 
genes; (2) patients may be unselected for family history; and (3) 
analysis and reporting in a tight time frame is typically required. 
A number of challenging issues have emerged, including
1. Categorisation and management of reduced penetrance vari-
ants in high- penetrance genes.
2. Variant interpretation and clinical management for moderate- 
penetrance genes.
3. Adaptation of variant interpretation and risk for different 
contexts of ascertainment.
4. Inference of germline findings from tumour- only sequencing.
While germane across genomics, consideration of these issues 
has become pressing within germline cancer genetics. Benefitting 
from its regular forum, multidisciplinary membership and align-
ment with both UK- ACGS and the UK Cancer Genetics Group 
(UK- CGG), we have used the CanVIG–UK monthly forum to 
evolve UK national multidisciplinary approaches on such issues 
(see online supplementary appendix 3).
development of an online platform to facilitate information 
sharing and variant interpretation within the uk clinical-
laboratory community
In germline cancer genetics, enrichment in cases (especially 
‘strong families’) is one of the most valuable clinical observa-
tions indicating variant pathogenicity. However, to date, we 
have struggled to quantify such observations on account of (1) 
failure to aggregate national data from distributed laboratories 
and (2) lack of a robust denominator.
In a collaborative venture between Public Health England 
(PHE) and the national network of molecular diagnostic labora-
tories, data from molecular testing of CSGs have been submitted 
via a pseudonymisation portal to the secure National Cancer 
Registration and Analysis Service (NCRAS) data environment of 
PHE.28 The national variant totals (numerator and denominator) 
are then shared by CanVIG- UK with the UK clinical- laboratory 
community via our online data system CanVar- UK (http://www. 
canvaruk. org/).
CanVar- UK provides additional annotations for 1 008 643 
variants from 95 CSGs. It includes variant- level annotations 
from LSDs (case counts), functional assays, splicing assays and 
multifactorial analyses for selected genes. Accessible only to 
registered CanVIG- UK clinical- laboratory users is a commu-
nity area for sharing non- identifiable variant- level data, such as 
local classifications, comments/notes, uploaded documents and 
results from local laboratory assays (eg, RNA analyses of poten-
tial splicing variants).
uk contribution to international variant interpretation 
endeavours
CanVIG- UK is an effective conduit between the UK clinical- 
laboratory germline cancer genetics community and relevant 
international variant interpretation endeavours in several 
regards:
 ► First, there is representation at the international ClinGen 
SVI group from the leadership of the UK- ACGS rare disease 
variant interpretation group. The regular crosstalk between 
leadership of the UK groups enables appraisal of the 
ClinGen SVI group of emerging analyses and activity within 
CanVIG- UK and the UK clinical- laboratory cancer genetics 
community.
 ► Second, multiple members of CanVIG- UK are members of 
gene- specific international endeavours such as ENIGMA, 
InSIGHT and ClinGen expert groups.
 ► Third, data generated by CanVIG- UK data have contrib-
uted to collaborative international consortia analyses, for 
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Figure 2 Perceived utility of CanViG- UK activities regarding local practice in CsG variant interpretation of seven activities (5: very useful to 1: not useful; 
survey of CanViG- UK members, performed on 29 october 2019, return rate 83/103 (81%)). aCGs, association of Clinical Genomic science; aCmG, american 
College of medical Geneticists; CanViG- UK, Cancer Variant interpretation Group UK; CsG, cancer susceptibility gene.
example, provision to ENIGMA of the summary PHE UK 
laboratory data on BRCA1/BRCA2 variants.
 ► Fourth, CanVIG- UK consensus classifications (and under-
pinning evidence) are shared via ClinVar. CanVIG- UK is the 
first UK organisation to submit clinical- laboratory variant 
classifications to ClinVar.
sustainability
Maintenance of a national multidisciplinary network, coordina-
tion of a regular teleconferenced MDMs and development of a 
data system is only feasible via sustained support. The activities 
of CanVIG- UK are currently supported by a Cancer Research 
UK Catalyst Award (CanGene- CanVar, @CangeneCanvar, 
C61296/A27223).
ConClusIon
CanVIG- UK is a multidisciplinary group comprising >100 clin-
ical scientists and senior genetics clinicians working in germ-
line cancer genetics, with representation from across the 25 
NHS molecular diagnostic laboratories of the UK and Ireland. 
Through CanVIG- UK, the UK clinical- laboratory germline 
cancer genetics community have evolved:
1. An email forum for real- time consultation on problematic 
variants.
2. A monthly teleconferenced MDM for detailed review of 
challenging variants and cases.
3. A national programme of using secure submissions of fre-
quency data from PHE.
4. An online data system (CanVar- UK) for sharing variant- level 
data both publicly and within a secure community region.
5. Detailed, consensus UK guidance for the interpretation of 
variants in CSGs.
6. Fruitful interactions with international CSG variant interpre-
tation endeavours.
In summary, we propose CanVIG- UK as an exemplar National 
Subspecialty Multidisciplinary Genomics Network. In this era 
of rapid emergence of genomic knowledge, such networks are 
becoming increasingly important to optimise collaborative 
specialist case review, information sharing and education.
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